Precigen's stock surged 16.77% during the night session on Wednesday, following the release of the company's full-year 2025 financial results and business updates.

The biopharmaceutical company reported its first commercial sales of PAPZIMEOS, the first-and-only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The drug generated $3.4 million in net product revenue in the fourth quarter of 2025, marking Precigen's transition from a clinical-stage to a commercial-stage company. Revenue for the full year reached $9.7 million, surpassing analyst expectations of $8.4 million.

Investors reacted positively to the strong commercial momentum, with management noting a significant increase in demand for PAPZIMEOS in the first quarter of 2026. Additional positive developments include the assignment of a permanent J-code for streamlined reimbursement effective April 1, 2026, and a Marketing Authorization Application under review by the European Medicines Agency. The company also stated its current cash position is expected to fund operations to cash flow break-even.